Hong Ri, Wu Yong-Qiang, Wu Yue
Zhongguo Zhong Yao Za Zhi. 2014 Mar;39(6):1120-3.
In order to explore the possibility of Xihuangwan (XHW)'s application in assistant therapy in patients with breast cancer, short- and long-term clinical efficacy were assessed in this study. Eighty and four patients with advanced breast cancer were selected in this study. They were divided into control group and treatment group randomly and evenly. All patients received surgical treatment followed by chemotherapy regimen composed of PTX + EPI + CTX (TEC regimen). Treatment group received additional assistant treatment of XHW. Short-term clinical efficacy was assessed by KPS, lesion stabilizing rate and side effects in 3-month follow-up study. Long-term clinical efficacy was assessed by overall survival (OS) and free-progression survival (FPS). KPS increased significantly after treatment in all patients (P < 0.05), more significantly in treatment group than in control group after treatment (P < 0.05); lesion stabilizing rate in treatment group increased significantly in treatment group than in control group (92.86% vs. 85.71%, P < 0.05); there was no significant difference between control group and treatment group in occurrence of side effects. Compared with control group, OS and FPS increased significantly in treatment group. Data in this study showed that XHW was suitable in treatment of advanced breast cancer due to its satisfactory short-term and long-term therapeutic effects.
为探讨西黄丸（XHW）在乳腺癌患者辅助治疗中的应用可能性，本研究评估了其短期和长期临床疗效。本研究选取了84例晚期乳腺癌患者，将其随机平均分为对照组和治疗组。所有患者均接受手术治疗，随后采用由紫杉醇（PTX）+表柔比星（EPI）+环磷酰胺（CTX）组成的化疗方案（TEC方案）。治疗组额外接受XHW辅助治疗。在3个月的随访研究中，通过卡氏功能状态评分（KPS）、病灶稳定率和副作用评估短期临床疗效。通过总生存期（OS）和无进展生存期（FPS）评估长期临床疗效。所有患者治疗后KPS均显著提高（P<0.05），治疗组治疗后KPS提高更显著，高于对照组（P<0.05）；治疗组病灶稳定率显著高于对照组（92.86%对85.71%，P<0.05）；对照组和治疗组副作用发生率无显著差异。与对照组相比，治疗组的OS和FPS显著提高。本研究数据表明，XHW因其满意的短期和长期治疗效果，适用于晚期乳腺癌的治疗。
